Leerink Partnrs Has Bearish Outlook for ARWR FY2026 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at Leerink Partnrs lowered their FY2026 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($0.92) for the year, down from their previous estimate of $0.10. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.97).

Other research analysts have also issued research reports about the stock. Sanford C. Bernstein decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Piper Sandler reduced their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. B. Riley restated a “buy” rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $14.80 on Thursday. Arrowhead Pharmaceuticals has a 52 week low of $14.23 and a 52 week high of $30.41. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm’s 50-day simple moving average is $18.58 and its 200 day simple moving average is $19.92. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -2.86 and a beta of 0.92.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now owns 272,122 shares in the company, valued at $5,393,458.04. The trade was a 10.74 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now owns 4,062,377 shares of the company’s stock, valued at $61,220,021.39. This represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 301,730 shares of company stock worth $5,352,844 in the last three months. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $38,000. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $49,000. Van ECK Associates Corp increased its holdings in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV raised its position in Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 1,644 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new position in Arrowhead Pharmaceuticals during the 4th quarter worth about $137,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.